Actuate Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow-2067.81%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Actuate Therapeutics (ACTU) currently reports a ROE of -2067.81%. That is below the sector sector average of 11.85%. Use the charts on this page to explore Actuate Therapeutics's ROE history and peer comparisons.
Actuate Therapeutics's ROE of -2067.81% is lower than the its sector sector average of 11.85%. That is roughly 17546.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Actuate Therapeutics's current -2067.81% should be judged against industry norms (sector average: 11.85%) and against ACTU's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -2067.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.85%. From there, open related valuation or income-statement pages for Actuate Therapeutics, and consider following ACTU for alerts when major investors trade the stock.
